Revised forecast
Fiscal year ending March 2027 · Full yearThe bar length represents the relative magnitude of change, based on the item that changed the most in this document.
The company expects sales of Leqembi and Dayvigo to expand and will continue growth investments, including the allocation of resources to important research and development projects, while pursuing greater cost efficiency.
Impairment loss of ¥1,403 million. The amount of inventory valuation losses and other expenses associated with the discontinuation of sales of Tazverik is not disclosed.
| Item | Details |
|---|---|
| Net Sales | Not disclosed → 883,500 Millions of yen（+7.0%） |
| Operating profit | Not disclosed → 70,000 Millions of yen（+58.6%） |
| Profit attributable to owners of the parent | Not disclosed → 52,300 Millions of yen（+35.6%） |
| Net income per share | Not disclosed → 185 yen and sen（+35.3%） |
| Fiscal Period Covered | Fiscal year ending March 2027 |
| Period Covered | Full year |
| Previous-period results | Revenue: ¥825,378 million; operating profit: ¥44,138 million; profit before tax: ¥50,999 million; profit attributable to owners of the parent: ¥38,558 million; basic earnings per share: ¥136.78 |
| Reason for the revision | The company expects sales of Leqembi and Dayvigo to expand and will continue growth investments, including the allocation of resources to important research and development projects, while pursuing greater cost efficiency. |
| Details and amount of extraordinary loss | Impairment loss of ¥1,403 million. The amount of inventory valuation losses and other expenses associated with the discontinuation of sales of Tazverik is not disclosed. |
| Dividend forecast revision | The annual dividend for the fiscal year ending March 2027 is ¥160, comprising an interim dividend of ¥80 and a year-end dividend of ¥80, unchanged from the current fiscal year. |
| Consolidated / non-consolidated | Consolidated |
Items this document does not state (2)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Operating profit declined in the fiscal year ended March 2026, reflecting the absence of the one-time payment related to the transfer of product rights and the gain associated with the termination of a strategic alliance recognized in the previous fiscal year, as well as investment in Leqembi and restructuring costs in Europe. For the fiscal year ending March 2027, the company expects earnings growth based on increased sales of Leqembi and Dayvigo, efficient spending and growth investments.